Patent US5286731A successfully refreshed from Google Patents.
US5286731A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treating immunoinflammatory bowel disease
Assignee: Wyeth LLC
•
Filing: 1992-08-17
•
Granted: 1994-02-15
•
Expires: 2012-08-17
Abstract
Abstract This invention provides a method of treating immunoinflammatory bowel disease in a mammal in need thereof which comprises administering an antiimmunoinflammatory amount of rapamycin, alone or in combination with cyclosporin A. As such, rapamycin, alone or in combination with cyclosporin A, is useful in treating bowel diseases such as ulcerative colitis, Crohn's disease, ulcerative proctitis, and the like.
Inventors
- 👤 Craig E. Caufield
- 👤 John H. Musser
- 👤 Surendra N. Sehgal
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 13:12
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/4353; A61K31/436; A61K31/70; A61K31/44; A61K31/445; A61K38/00; A61K38/04; A61K38/12; A61K38/13; A61P; A61P1/00; A61P1/04; A61P37/00
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
32 words
A method of treating immunoinflammatory bowel disease in a mammal in need thereof which comprises administering an antiimmunoinflammatory amount of rapamycin orally, parenterally, intranasally, intrabronchially, topically, transdermally, or rectally to said mammal.
Claim 2
Independent Claim
32 words
A method of treating immunoinflammatory bowel disease in a mammal in need thereof which comprises administering an antiimmunoinflammatory amount of rapamycin orally, parenterally, intranasally, intrabronchially, topically, transdermally, or rectally to said mammal.
Claim 3
Dependent Claim
18 words
The method according to claim 1 wherein the bowel disease is ulcerative colitis, Crohn's disease, or ulcerative proctitis.
Claim 4
Independent Claim
41 words
A method of providing symptomatic relief of, preventing the progression of, or eradicating immunoinflammatory bowel disease in a mammal in need thereof which comprises administering an antiimmunoinflammatory amount of rapamycin orally, parenterally, intranasally, intrabronchially, topically, transdermally, or rectally to said mammal.
Claim 5
Independent Claim
41 words
A method of providing symptomatic relief of, preventing the progression of, or eradicating immunoinflammatory bowel disease in a mammal in need thereof which comprises administering an antiimmunoinflammatory amount of rapamycin orally, parenterally, intranasally, intrabronchially, topically, transdermally, or rectally to said mammal.
Claim 6
Dependent Claim
18 words
The method according to claim 3 wherein the bowel disease is ulcerative colitis, Crohn's disease, or ulcerative proctitis.
Claim 7
Independent Claim
38 words
A method of treating immunoinflammatory bowel disease in a mammal in need thereof which comprises administering an antiimmunoinflammatory amount of a combination of rapamycin and cyclosporin A orally, parenterally, intranasally, intrabronchially, topically, transdermally, or rectally to said mammal.
Claim 8
Independent Claim
38 words
A method of treating immunoinflammatory bowel disease in a mammal in need thereof which comprises administering an antiimmunoinflammatory amount of a combination of rapamycin and cyclosporin A orally, parenterally, intranasally, intrabronchially, topically, transdermally, or rectally to said mammal.
Claim 9
Dependent Claim
18 words
The method according to claim 5 wherein the bowel disease is ulcerative colitis, Crohn's disease, or ulcerative proctitis.
Claim 10
Independent Claim
47 words
A method of providing symptomatic relief of, preventing the progression of, or eradicating immunoinflammatory bowel disease in a mammal in need thereof which comprises administering an antiimmunoinflammatory amount of a combination of rapamycin and cyclosporin A orally, parenterally, intranasally, intrabronchially, topically, transdermally, or rectally to said mammal.
Claim 11
Independent Claim
47 words
A method of providing symptomatic relief of, preventing the progression of, or eradicating immunoinflammatory bowel disease in a mammal in need thereof which comprises administering an antiimmunoinflammatory amount of a combination of rapamycin and cyclosporin A orally, parenterally, intranasally, intrabronchially, topically, transdermally, or rectally to said mammal.
Claim 12
Dependent Claim
18 words
The method according to claim 7 wherein the bowel disease is ulcerative colitis, Crohn's disease, or ulcerative proctitis.
References Cited (Backward Citations)
US3929992A
Cited
EP0315978A2
Cited
US4996193A
Cited
US5023264A
Cited
US5023263A
Cited
WO1992002229A1
Cited
US5078999A
Cited
US5080899A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-02-14 | 1997-08-16 | 1998-02-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-02-14 | 2001-08-16 | 2002-02-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-02-14 | 2005-08-16 | 2006-02-15 | $7700.00 | Window Closed / Lapsed |